Shots:
- Zoetis has reported the self-sponsored UK trial data on Librela (bedinvetmab) to manage canine osteoarthritis (OA) pain
- Trial assessed Librela (n=52) vs meloxicam (n=49) over 8wks in newly or previously diagnosed OA dogs (N=101), who only received nutraceuticals, evaluating COI score changes as the 1EP; AE differences were inconclusive due to small sample size & short study duration
- Trial showed Librela & meloxicam managed OA pain from Day 14, with both improving over 56 days period. More dogs completed the study in Librela arm (44 vs 33), & while COI score reductions favored Librela, the difference was insignificant; data published in the Frontiers in Veterinary Science
Ref: Zoetis | Image: Zoetis
Related News:- Zoetis Collaborates with Danone to Develop Sustainable Practices in Dairy Farming Using Genetic Innovation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
